NCI’s Clinical Trials Cooperative Groups National Meetings Report

The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**COG ANBL00B1**: The ALK gene, a known oncogene previously associated with anaplastic large cell lymphoma and a subset of lung cancers, was shown to be the cause of most cases of familial neuroblastoma. Moreover, ALK genomic alterations, including gene amplification and activating point mutations, were demonstrated as somatic changes in a subset of high-risk neuroblastoma tumors. These discoveries have obvious therapeutic implications, as small molecule inhibitors of ALK have entered clinical evaluations in adults with cancer. (Other Cancer/COG/ Mosse et al.)

**COG AEWS0031**: Standard therapy for patients with localized Ewing sarcoma family tumors (ESFT) previously consisted of every 3 week administration of either vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide. Intensification of therapy was achieved by compressing the interval of chemotherapy administration to every 2 weeks. This resulted in a statistically significant improvement in the 3 year EFS from 65% (std timing) as compared to 76% (compressed timing) (p=0.028) in this prospectively randomized trial. Improvements continue to be seen in patients with localized EFS. (Sarcoma/Bone and Soft Tissue Cancers/COG/Womer et al.)
Cooperative Group Abstracts

Breast Cancer

**ACOSOG**


Protocol(s): ACOSOG-Z0010

**ACRIN**


Protocol(s): ACRIN-6666


[http://www.ismrm.org/08/index.htm](http://www.ismrm.org/08/index.htm)

Protocol(s): ACRIN-6657

**CALGB**


Protocol(s): CALGB-49907


Protocol(s): CALGB-49907


Protocol(s): CALGB-79809
ECOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33166
Protocol(s): E2197

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33989
Protocol(s): E2100

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30295
Protocol(s): E2104

NCCTG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35739
Protocol(s): Multiple Trials

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32705
Protocol(s): NCCTG-89-30-52

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30232
Protocol(s): N02C1
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35549
Protocol(s): N0436

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35657
Protocol(s): N03CC

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35184
Protocol(s): N9831

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35315
Protocol(s): N0437

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35214
Protocol(s): NSABP-B-31, N9831

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31083
Protocol(s): N0338

NCIC Clinical Trials Group

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33209
Protocol(s): NCIC-MA.12
**NSABP**


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35746

Protocol(s): NSABP-P-2


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35097

Protocol(s): NSABP-B-24


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35171

Protocol(s): NSABP-B-32


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35214

Protocol(s): N9831, NSABP-B-31


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31334

Protocol(s): NSABP-B-25, NSABP-B-22, NSABP-B-28, NSABP-B-31

**SWOG**


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33986

Protocol(s): S0102

**CNS Cancer**

**NCCTG**


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31388

Protocol(s): N0177

RTOG


Gastrointestinal Cancer

ACOSOG


ACRIN

Galen B: CT Colonography: Science to Practice on the U.S., Helsinger, Denmark, June, 2008.
http://appliedresearch.cancer.gov/icsn/meetings/2008/
Protocol(s): ACRIN-6664

CALGB

de Gramont A: Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,800 patient (pt) ACCENT dataset. J Clin Oncol 2008; 26(Suppl):Abst.4007.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35362
Protocol(s): C89803, NSABP-C-01, NSABP-C-03, NSABP-C-02, NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33374
Protocol(s): C89803

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31778
Protocol(s): CALGB-80203

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35166
Protocol(s): CALGB-80402

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32729
Protocol(s): CALGB-80603

COG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33950
Protocol(s): INT-0098
**ECOG**


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30912 Protocol(s): E6202


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33368 Protocol(s): E8200


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31710 Protocol(s): E1201


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30957 Protocol(s): E4201


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31775 Protocol(s): E5203

**NCCTG**


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34527 Protocol(s): N014A
de Gramont A: Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,800 patient (pt) ACCENT dataset. J Clin Oncol 2008; 26(Suppl):Abst.4007. 
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35362 Protocol(s): NSABP-C-01, NSABP-C-03, NSABP-C-02, NSABP-C-04, NSABP-C-05, C89803, NSABP-C-07, NSABP-C-06

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10575 Protocol(s): N9741

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35888 Protocol(s): N0349

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10804 Protocol(s): N0349

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32445 Protocol(s): N04C7

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34993 Protocol(s): N9741

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10531 Protocol(s): N9741


NSABP


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10623  
Protocol(s): NSABP-C-07

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30044  
Protocol(s): NSABP-C-07

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35795  
Protocol(s): NSABP-LTS-01, NSABP-C-07

RTOG

http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={915A7C40-23A5-4C4C-B908-3C48ED272771}&SKey={968421CB-8CD7-4729-AD5B-DD80813AA804}&MKey={9EE8A828-2B9E-4B30-997A-E97A0A4C2FEC}&AKey={728BCE9C-121B-46B9-A8EE-DC51FDFC6C15}  
Protocol(s): RTOG-97-04

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31098  
Protocol(s): RTOG-0247

SWOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10023  
Protocol(s): S0415
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30811
Protocol(s): S0415

Protocol(s): INT-0144/SWOG-9304

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10366
Protocol(s): INT-0144/SWOG-9304

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10495
Protocol(s): INT-0144/SWOG-9304

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33652
Protocol(s): INT-0144/SWOG-9304

Genitourinary Cancer

CALGB

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20388
Protocol(s): CALGB-90006, CALGB-9182, CALGB-90004, CALGB-9680, CALGB-99813, CALGB-9583, CALGB-9480, CALGB-9181, CALGB-9780
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20357  
Protocol(s): CALGB-90206

**ECOG**

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35359  
Protocol(s): E5803

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31628  
Protocol(s): E1804

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20372  
Protocol(s): E5803

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31403  
Protocol(s): E3803

**RTOG**

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33550  
Protocol(s): RTOG-92-02

**SWOG**

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20243  
Protocol(s): SWOG-8949
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32157
Protocol(s): SWOG-8949

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20310
Protocol(s): S9916, INT-0162/SWOG-9346

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32059
Protocol(s): S9916, INT-0162/SWOG-9346

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32346
Protocol(s): S0219

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31466
Protocol(s): S0317

Gynecologic Cancer

GOG

http://www.sgo.org/content.aspx?id=886
Protocol(s): GOG-0114

http://www.sgo.org/content.aspx?id=886
Protocol(s): GOG-0158
Protocol(s): GOG-0157

Protocol(s): GOG-0157

Protocol(s): GOG-0107

Protocol(s): GOG-0170D

[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=36264](http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=36264)
Protocol(s): GOG-0170D

Protocol(s): GOG-0184

Protocol(s): GOG-0172
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32581
Protocol(s): GOG-0182

http://www.sgo.org/content.aspx?id=886
Protocol(s): GOG-0172

http://www.sgo.org/content.aspx?id=886
Protocol(s): GOG-37

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33281
Protocol(s): GOG-0170F

Protocol(s): GOG-0127T

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31946
Protocol(s): GOG-0126Q

http://www.sgo.org/content.aspx?id=886
Protocol(s): GOG-0227C


NCIC Clinical Trials Group

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32681  
Protocol(s): NCIC-185

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34670  
Protocol(s): NCIC-160

Head and Neck Cancer

ECOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31585  
Protocol(s): E3303

Leukemia, Myelodysplasia, and Transplantation

CALGB

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31443  
Protocol(s): CALGB-19808, CALGB-9621

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33927  
Protocol(s): C9710
COG

Protocol(s): POG-9905, POG-9906, POG-9904

Protocol(s): CCG-1961

Protocol(s): AALL00P2

Protocol(s): POG-9421

Protocol(s): POG-9900

Protocol(s): Multiple Trials
Lymphoma and Plasma Cell Disorders

**CALGB**

Protocol(s): CALGB-59909

**ECOG**

Protocol(s): AMC-034

Protocol(s): E4A03

**NCCTG**

[https://www.lymphcon.ch/](https://www.lymphcon.ch/)  
Protocol(s): N0489

Protocol(s): N0489
SWOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36278
Protocol(s): S0232

Lung Cancer

CALGB

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36075
Protocol(s): CALGB-30407

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33570
Protocol(s): Multiple Trials

ECOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33917#
Protocol(s): E6501

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35210
Protocol(s): E4599

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32202
Protocol(s): E3503
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=34195
Protocol(s): E4599

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=31135
Protocol(s): E2501

NCCTG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=33284
Protocol(s): N0426

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=32144
Protocol(s): N0423

NCIC Clinical Trials Group

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=30437
Protocol(s): JBR10

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=31961
Protocol(s): CALGB-150802, JBR10

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=55&abstractId=32591
Protocol(s): JBR10
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32591  
Protocol(s): JBR10

RTOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36161  
Protocol(s): RTOG-0324

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30610  
Protocol(s): RTOG-0324

SWOG

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31238  
Protocol(s): S0435

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30235  
Protocol(s): S0222

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35772  
Protocol(s): S0124
Protocol(s): S0126

Melanoma/Skin Cancers

NCCTG

Protocol(s): N057E

SWOG

Protocol(s): S0508

Sarcoma/Bone and Soft Tissue Cancers

COG

Protocol(s): INT-0133

Protocol(s): AEWS0031
RTOG


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33436

Protocol(s): RTOG-0330

SWOG


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32180

Protocol(s): S0505


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30618

Protocol(s): S0345

Other Cancer

CALGB


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35926

Protocol(s): Multiple Trials

COG


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35066

Protocol(s): ADVL0516


http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33721

Protocol(s): ADVL0612


ECOG

NCCTG


RTOG


NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators


DCTD and DCP Activities

Scientific


Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.